Institutional Ownership
Spyglass Pharma Inc
CUSIP 85220G109COM SHSQ1 2026
13D / 13G Filings
6
Schedule 13D/13G on record
Beneficial Filers
6
Distinct reporting persons
Largest Stake
24.1%
Max % of class reported
Institutional Holders
31
13F filers (latest quarter)
Beneficial Owners — Schedule 13D / 13G
6 filings · latest Feb 17, 2026
| # | Filed | Reporting Person | Form | % of Class | Shares | Filing |
|---|---|---|---|---|---|---|
| 1 | Feb 17, 2026 | Samsara Biocapital, L.P. | 13G | 6.3% | 2.11M | SEC |
| 2 | Feb 17, 2026 | Ra Capital Management, L.P. | 13D | 24.1% | — | SEC |
| 3 | Feb 13, 2026 | Sands Capital Life Sciences Pulse Fund III (De), L.P. | 13G | 7.8% | 2.50M | SEC |
| 4 | Feb 13, 2026 | Gilde Healthcare Holding B.V. | 13D | 6.6% | — | SEC |
| 5 | Feb 13, 2026 | New Enterprise Associates 17, L.P. | 13D | 22.2% | — | SEC |
| 6 | Feb 10, 2026 | Vensana Capital I Gp, LLC | 13D | 9.9% | — | SEC |
Top Institutional Holders (13F)
Largest reported positions · latest quarter
| # | Fund | Shares | Value |
|---|---|---|---|
| 1 | Ra Capital Management, L.P. | 8.02M | $207.83M |
| 2 | Nea Management Company, LLC | 7.39M | $191.53M |
| 3 | Sands Capital Alternatives, LLC | 2.50M | $64.78M |
| 4 | Samsara Biocapital, LLC | 2.11M | $54.67M |
| 5 | Vestal Point Capital, LP | 666.8K | $17.28M |
| 6 | Deerfield Management Company, L.P. | 550.0K | $14.25M |
| 7 | Jpmorgan Chase & Co | 577.1K | $13.49M |
| 8 | Millennium Management LLC | 468.8K | $12.15M |
| 9 | First Light Asset Management, LLC | 375.0K | $9.72M |
| 10 | Franklin Resources Inc | 300.0K | $7.77M |